Literature DB >> 21077673

Polymer-caged nanobins for synergistic cisplatin-doxorubicin combination chemotherapy.

Sang-Min Lee1, Thomas V O'Halloran, SonBinh T Nguyen.   

Abstract

Multicomponent chemotherapy has increasingly become a strategy of great importance in clinical cancer treatments. However, this type of chemotherapy has not been demonstrated in nanoscale delivery vehicles where two cytotoxic agents can be packaged together, potentially leading to synergistic drug activities. Herein, we present the codelivery of doxorubicin and cisplatin via a single polymer-caged nanobin (PCN) and show that copackaging can yield strong synergy in the efficacy of these agents. Such a PCN comprises a doxorubicin-encapsulated liposomal core protected by a pH-responsive cisplatin prodrug-loaded polymer shell with tunable drug ratios and surface charge potentials. This dual-agent Pt-PCN(DXR) formulation dramatically enhances the overall cytotoxicity of each drug against cancer cells at reduced doses and exhibits higher synergy than combinations of either the free drugs or separately nano-packaged drugs. These results clearly indicate that the polymer-caged nanobin platform can offer new means for building synergy into combination chemotherapy regimens.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21077673      PMCID: PMC3657616          DOI: 10.1021/ja107333g

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  45 in total

1.  Micellar nanocontainers distribute to defined cytoplasmic organelles.

Authors:  Radoslav Savic; Laibin Luo; Adi Eisenberg; Dusica Maysinger
Journal:  Science       Date:  2003-04-25       Impact factor: 47.728

2.  A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer.

Authors:  E S Kim; C Lu; F R Khuri; M Tonda; B S Glisson; D Liu; M Jung; W K Hong; R S Herbst
Journal:  Lung Cancer       Date:  2001-12       Impact factor: 5.705

3.  Four-year analysis of platinum and anthracycline combination for ovarian cancer.

Authors:  A Martoni; A Bellucco; N Canova; F Pannuti
Journal:  Oncology       Date:  1989       Impact factor: 2.935

4.  Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies.

Authors:  O Lyass; A Hubert; A A Gabizon
Journal:  Clin Cancer Res       Date:  2001-10       Impact factor: 12.531

Review 5.  A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles.

Authors:  D N Waterhouse; P G Tardi; L D Mayer; M B Bally
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

6.  Nanocapsules: lipid-coated aggregates of cisplatin with high cytotoxicity.

Authors:  Koert N J Burger; Rutger W H M Staffhorst; Hanke C de Vijlder; Maria J Velinova; Paul H Bomans; Peter M Frederik; Ben de Kruijff
Journal:  Nat Med       Date:  2002-01       Impact factor: 53.440

7.  Acid pH in tumors and its potential for therapeutic exploitation.

Authors:  I F Tannock; D Rotin
Journal:  Cancer Res       Date:  1989-08-15       Impact factor: 12.701

8.  Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma.

Authors:  William C Zamboni; Anne C Gervais; Merrill J Egorin; Jan H M Schellens; Elleanor G Zuhowski; Dick Pluim; Erin Joseph; Deborah R Hamburger; Peter K Working; Gail Colbern; Margaret E Tonda; Douglas M Potter; Julie L Eiseman
Journal:  Cancer Chemother Pharmacol       Date:  2003-12-12       Impact factor: 3.333

9.  Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study.

Authors:  J Tate Thigpen; Mark F Brady; Howard D Homesley; John Malfetano; Brent DuBeshter; Robert A Burger; Shu Liao
Journal:  J Clin Oncol       Date:  2004-10-01       Impact factor: 44.544

Review 10.  Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity.

Authors:  Giorgio Minotti; Pierantonio Menna; Emanuela Salvatorelli; Gaetano Cairo; Luca Gianni
Journal:  Pharmacol Rev       Date:  2004-06       Impact factor: 25.468

View more
  34 in total

1.  Nanoparticles with Precise Ratiometric Co-Loading and Co-Delivery of Gemcitabine Monophosphate and Cisplatin for Treatment of Bladder Cancer.

Authors:  Lei Miao; Shutao Guo; Jing Zhang; William Y Kim; Leaf Huang
Journal:  Adv Funct Mater       Date:  2014-11-12       Impact factor: 18.808

Review 2.  Stimuli-responsive nanocarriers for drug delivery.

Authors:  Simona Mura; Julien Nicolas; Patrick Couvreur
Journal:  Nat Mater       Date:  2013-11       Impact factor: 43.841

3.  Smart Nanoscale Drug Delivery Platforms from Stimuli-Responsive Polymers and Liposomes.

Authors:  Sang-Min Lee; SonBinh T Nguyen
Journal:  Macromolecules       Date:  2013-11-27       Impact factor: 5.985

4.  Tumor microenvironment and nanotherapeutics.

Authors:  Meenakshi Upreti; Amar Jyoti; Pallavi Sethi
Journal:  Transl Cancer Res       Date:  2013-08-01       Impact factor: 1.241

Review 5.  Nanocarriers for delivery of platinum anticancer drugs.

Authors:  Hardeep S Oberoi; Natalia V Nukolova; Alexander V Kabanov; Tatiana K Bronich
Journal:  Adv Drug Deliv Rev       Date:  2013-10-08       Impact factor: 15.470

6.  Hyaluronan-Lysine Cisplatin Drug Carrier for Treatment of Localized Cancers: Pharmacokinetics, Tolerability, and Efficacy in Rodents and Canines.

Authors:  Ti Zhang; Shuang Cai; Chad Groer; Wai Chee Forrest; Qiuhong Yang; Eva Mohr; Justin Douglas; Daniel Aires; Sandra M Axiak-Bechtel; Kimberly A Selting; Jeffrey A Swarz; Deborah J Tate; Jeffrey N Bryan; M Laird Forrest
Journal:  J Pharm Sci       Date:  2016-05-04       Impact factor: 3.534

7.  E-Jet 3D-Printed Scaffolds as Sustained Multi-Drug Delivery Vehicles in Breast Cancer Therapy.

Authors:  Xiaoyin Qiao; Yikun Yang; Ruiying Huang; Xuelei Shi; Haoxiang Chen; Jian Wang; Yanxiang Chen; Yongjun Tan; Zhikai Tan
Journal:  Pharm Res       Date:  2019-11-18       Impact factor: 4.200

8.  Acid-degradable polymer-caged lipoplex (PCL) platform for siRNA delivery: facile cellular triggered release of siRNA.

Authors:  Bong Jin Hong; Anthony J Chipre; SonBinh T Nguyen
Journal:  J Am Chem Soc       Date:  2013-11-13       Impact factor: 15.419

9.  DNA Polyplexes as Combinatory Drug Carriers of Doxorubicin and Cisplatin: An in Vitro Study.

Authors:  Han Chang Kang; Hana Cho; You Han Bae
Journal:  Mol Pharm       Date:  2015-07-13       Impact factor: 4.939

10.  Highly Stable, Ultrasmall Polymer-Grafted Nanobins (usPGNs) with Stimuli-Responsive Capability.

Authors:  Bong Jin Hong; Aysenur Iscen; Anthony J Chipre; Mei Mei Li; One-Sun Lee; Joshua N Leonard; George C Schatz; SonBinh T Nguyen
Journal:  J Phys Chem Lett       Date:  2018-02-19       Impact factor: 6.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.